59
Participants
Start Date
November 30, 2010
Primary Completion Date
July 31, 2015
Study Completion Date
July 31, 2015
Rivaroxaban (Xarelto, BAY59-7939)
Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
Crumlin
Vienna
Parkville
Linz
Brisbane
Basel
Torino
New Hyde Park
Pittsburgh
Genova
Philadelphia
Milan
Lübeck
Pavia
Chapel Hill
Durham
Toulouse
Gainesville
St. Petersburg
Montpellier
Indianapolis
Indianapolis
Chicago
Clermont-Ferrand
Paris
Los Angeles
Orange
Tel Litwinsky
Jerusalem
Little Rock
Los Angeles
Detroit
Cleveland
Edmonton
Hamilton
Toronto
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY